- Previous Close
0.1000 - Open
0.0200 - Bid 0.0201 x --
- Ask 0.0750 x --
- Day's Range
0.0200 - 0.0200 - 52 Week Range
0.0200 - 0.0200 - Volume
15,000 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
nkgenbiotech.comRecent News: NKGNW
View MoreCompare To: NKGNW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKGNW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-97.34%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-48.48M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
8k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-31.33M